Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02458287 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 299
- Enrollment target
NCT02458287 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 299 participants.
The verdict
NCT02458287, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 299 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).
Interventions
- BIOLOGICAL Bococizumab 150mg
- BIOLOGICAL Bococizumab 75mg
- BIOLOGICAL Bococizumab 150mg placebo
- BIOLOGICAL Bococizumab 75mg placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02458287
The ClinicalTrials.gov registry entry for NCT02458287 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bococizumab 150mg is the first listed.
NCT02458287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02458287 about?
NCT02458287 is a clinical study titled "Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia". This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).
What is the current status of trial NCT02458287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 2015-06. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02458287?
The interventions under investigation include: Bococizumab 150mg (BIOLOGICAL), Bococizumab 75mg (BIOLOGICAL), Bococizumab 150mg placebo (BIOLOGICAL), Bococizumab 75mg placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02458287?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.